More Than 230,000 Bottles of a Popular Antidepressant Have Been Recalled Nationwide

More Than 230,000 Bottles of a Popular Antidepressant Have Been Recalled Nationwide

As society rightly challenges the stigmas surrounding mental health, many individuals are now getting the help they need to treat their psychologic conditions. In particular, the National Institutes of Health notes that depressive disorders are among the most common conditions in the United States, affecting at least 21 million Americans each year. Further, according to data from the Centers for Disease Control and Prevention (CDC), 13% of  surveyed adults reported taking anti-depressant drugs within the 30 days prior.

Given the high prevalence of antidepressant prescriptions, a new recall has sparked concern over one particular type of drug. On November 19, the East Brunswick, NJ-based drug manufacturer Rising Pharma, Inc., issued a voluntary recall of more than 230,000 bottles of duloxetine, one of the most common SNRIs (serotonin and norepinephrine reuptake inhibitors). The Cleveland Clinic notes that brand names include of duloxetine include Cymbalta, Drizalma, and Irenka. It’s been stated by one doctor of pharmacy publishing market research that over 4,000,000 Americans took duloxetine in 2022, resulting in more than 18,000,000 prescriptions. This makes it approximately the 31st most-prescribed drugs in America.

The FDA reports that the recall was initiatiated after it was discovered that the products contained elevated levels of N-nitroso-duloxetine (NDXT), which has been identified as potentially carcinogenic when present in high concentrations and ingested over a long period of time.

Pages: 1 2 3 4

RSS
Follow by Email